DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$180.8m

DiaMedica Therapeutics Management

Management criteria checks 3/4

DiaMedica Therapeutics' CEO is Rick Pauls, appointed in Jan 2010, has a tenure of 14.83 years. total yearly compensation is $1.22M, comprised of 46.2% salary and 53.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $290.13K. The average tenure of the management team and the board of directors is 2.2 years and 5.5 years respectively.

Key information

Rick Pauls

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage46.2%
CEO tenure14.8yrs
CEO ownership0.2%
Management average tenure2.2yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

CEO Compensation Analysis

How has Rick Pauls's remuneration changed compared to DiaMedica Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$562k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$1mUS$523k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$477k

-US$14m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$878kUS$455k

-US$12m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$420k

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$734kUS$315k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$502kUS$280k

-US$4m

Compensation vs Market: Rick's total compensation ($USD1.22M) is about average for companies of similar size in the US market ($USD1.49M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.

CEO

Rick Pauls (53 yo)

14.8yrs

Tenure

US$1,215,161

Compensation

Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...

Leadership Team

NamePositionTenureCompensationOwnership
Dietrich Pauls
President14.8yrsUS$1.22m0.16%
$ 290.1k
Scott Kellen
CFO & Corporate Secretary6.6yrsUS$632.22k0.076%
$ 136.6k
Ambarish Shah
Chief Technology Officer1.2yrsno datano data
Dominic Cundari
Chief Commercial Officer2.8yrsno data0.0066%
$ 11.8k
David Wambeke
Chief Business Officer1.6yrsno data1.23%
$ 2.2m
Lorianne Masuoka
Chief Medical Officerless than a yearno datano data

2.2yrs

Average Tenure

59yo

Average Age

Experienced Management: DMAC's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dietrich Pauls
President19.6yrsUS$1.22m0.16%
$ 290.1k
James Parsons
Independent Director9.1yrsUS$97.18k0.0053%
$ 9.5k
R. Giuffre
Independent Director14.3yrsUS$90.93k0.76%
$ 1.4m
George L. Bakris
Member of Kidney Scientific Advisory Board5.5yrsno datano data
Richard Pilnik
Independent Chairman15.5yrsUS$133.98k0.33%
$ 598.3k
Glenn Chertow
Member of Kidney Scientific Advisory Board5.5yrsno datano data
Rajiv Agarwal
Member of Kidney Scientific Advisory Board5.5yrsno datano data
Philip Bath
Member of Stroke Advisory Board1.8yrsno datano data
Scott Kasner
Member of Stroke Clinical Advisory Boardno datano datano data
Charles Herzog
Member of Kidney Scientific Advisory Boardno datano datano data
John Volpi
Member of Stroke Clinical Advisory Boardno datano datano data
Aldo Peixoto
Member of Kidney Scientific Advisory Board5.5yrsno datano data

5.5yrs

Average Tenure

63yo

Average Age

Experienced Board: DMAC's board of directors are considered experienced (5.5 years average tenure).